FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1845331805> ?p ?o ?g. }

• W1845331805 endingPage "1630" @default.
• W1845331805 startingPage "1628" @default.
• W1845331805 abstract "Back to table of contents Previous article Next article No AccessD-cycloserine added to clozapine for patients with schizophreniaPublished Online:1 Apr 2006https://doi.org/10.1176/ajp.153.12.1628AboutSectionsView articleAbstractPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail View articleAbstractOBJECTIVE: The effects of D-cycloserine added to clozapine were assessed and compared with previous results for D-cycloserine plus conventional neuroleptics. METHOD: Ten schizophrenic outpatients receiving clozapine entered consecutive 2-week trials of placebo and D- cycloserine at 5, 15, 50, and 250 mg/day. Clinical evaluations were videotaped and scored by a rater blind to the sequence of assessments. RESULTS: There was a significant dose effect of D-cycloserine on scores on the Scale for the Assessment of Negative Symptoms (SANS); the 50-mg dose produced a mean 21% increase in SANS score. The patients had significantly higher baseline serum glutamate concentrations than the patients receiving typical neuroleptics in the previous trial. Baseline glutamate level and change in glycine level significantly correlated with response of negative symptoms to 50-mg D-cycloserine. CONCLUSIONS: The improvement of negative symptoms with D-cycloserine previously observed in patients receiving typical neuroleptics did not occur in patients treated with clozapine. Access content To read the fulltext, please use one of the options below to sign in or purchase access. Personal login Institutional Login Sign in via OpenAthens Purchase Save for later Item saved, go to cart PPV Articles - American Journal of Psychiatry $35.00 Add to cart PPV Articles - American Journal of Psychiatry Checkout Please login/register if you wish to pair your device and check access availability. Not a subscriber? Subscribe Now / Learn More PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development. Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.). FiguresReferencesCited byDetailsCited byFractal Structure of Brain Electrical Activity of Patients With Mental Disorders13 July 2022 | Frontiers in Physiology, Vol. 13Altered Brain Criticality in Schizophrenia: New Insights From Magnetoencephalography28 March 2022 | Frontiers in Neural Circuits, Vol. 16Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia1 October 2021 | Frontiers in Psychiatry, Vol. 12Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia12 April 2021 | Frontiers in Neuroscience, Vol. 15Characteristics and definitions of ultra-treatment-resistant schizophrenia – A systematic review and meta-analysisSchizophrenia Research, Vol. 228Current understanding on the role of nitric oxide and therapeutic potential of NO supplementation in schizophreniaSchizophrenia Research, Vol. 222The glycine site of NMDA receptors: A target for cognitive enhancement in psychiatric disordersProgress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 92Treatment of Clozapine Nonresponders23 January 2019 | Current Treatment Options in Psychiatry, Vol. 6, No. 1Biological Psychiatry, Vol. 86, No. 7Personalized Medicine in Psychiatry, Vol. 15-16Room to move: Plasticity in early auditory information processing and auditory learning in schizophrenia revealed by acute pharmacological challengeSchizophrenia Research, Vol. 199D-Cycloserine: A Novel Antidepressant to Be Explored?Psychiatric Annals, Vol. 48, No. 4Association of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study12 July 2017 | BMC Psychiatry, Vol. 17, No. 1Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia23 March 2017 | Cochrane Database of Systematic Reviews, Vol. 2017, No. 3, Vol. 76Psychiatric Clinics of North America, Vol. 39, No. 2International Journal of Neuropsychopharmacology, Vol. 19, No. 4Schizophrenia drug discovery and development in an evolving era: Are new drug targets fulfilling expectations?13 January 2015 | Journal of Psychopharmacology, Vol. 29, No. 2European Neuropsychopharmacology, Vol. 25, No. 8Translating the Glutamatergic Hypothesis of Schizophrenia Through Homeostatic Regulation of Brain GlycineExpert Opinion on Pharmacotherapy, Vol. 15, No. 16Evidence of Glutamatergic Dysfunction in the Pathophysiology of Schizophrenia29 July 2014World Psychiatry, Vol. 12, No. 2Schizophrenia Research, Vol. 150, No. 2-3Neurodevelopmental Role for VGLUT2 in Pyramidal Neuron Plasticity, Dendritic Refinement, and in Spatial Learning7 November 2012 | The Journal of Neuroscience, Vol. 32, No. 45Different serine and glycine metabolism in patients with schizophrenia receiving clozapineJournal of Psychiatric Research, Vol. 46, No. 6, Vol. 213European Neuropsychopharmacology, Vol. 22, No. 3Pharmacology Biochemistry and Behavior, Vol. 100, No. 4Schizophrenia Bulletin, Vol. 38, No. 5Schizophrenia Bulletin, Vol. 38, No. 5Expert Review of Neurotherapeutics, Vol. 12, No. 7Biomolecules and Therapeutics, Vol. 20, No. 1¿Estamos estudiando y tratando correctamente la esquizofrenia?Psiquiatría Biológica, Vol. 18, No. 4Neuroscience and Behavioral Physiology, Vol. 41, No. 6Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 35, No. 1Schizophrenia Research, Vol. 130, No. 1-3CNS Drugs, Vol. 25, No. 10, Vol. 4Neuroscience & Biobehavioral Reviews, Vol. 34, No. 3La memoria de extinción está deteriorada en la esquizofreniaPsiquiatría Biológica, Vol. 17, No. 1Psychiatry Research, Vol. 176, No. 2-3Clozapine versus typical neuroleptic medication for schizophrenia21 January 2009 | Cochrane Database of Systematic Reviews, Vol. 160Psychopharmacology, Vol. 202, No. 1-3Biological Psychiatry, Vol. 65, No. 6Psychiatry Research: Neuroimaging, Vol. 173, No. 2Neuropsychopharmacology, Vol. 34, No. 8Psychopharm Review, Vol. 44, No. 3Brazilian Journal of Medical and Biological Research, Vol. 42, No. 11New Approaches to Treatment of Schizophrenia by Enhancing N-methyl-D-aspartate Neurotransmission22 May 2007 | Progress in Neurotherapeutics and Neuropsychopharmacology, Vol. 3, No. 01Current Psychiatry Reports, Vol. 10, No. 4European Neuropsychopharmacology, Vol. 18, No. 5Journal of Liposome Research, Vol. 18, No. 3Expert Review of Neurotherapeutics, Vol. 8, No. 9On the Hypes and Falls in Neuroprotection: Targeting the NMDA Receptor2 October 2007 | The Neuroscientist, Vol. 13, No. 6The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): The Efficacy of Glutamatergic Agents for Negative Symptoms and Cognitive ImpairmentsRobert W. Buchanan, M.D.Daniel C. Javitt, M.D., Ph.D.Stephen R. Marder, M.D.Nina R. Schooler, Ph.D.James M. Gold, Ph.D.Robert P. McMahon, Ph.D.Uriel Heresco-Levy, M.D.William T. Carpenter, M.D.1 October 2007 | American Journal of Psychiatry, Vol. 164, No. 10The pipeline and future of drug development in schizophrenia31 July 2007 | Molecular Psychiatry, Vol. 12, No. 10Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?2 July 2016 | Journal of Psychopharmacology, Vol. 21, No. 3European Archives of Psychiatry and Clinical Neuroscience, Vol. 258, No. 1L'Encéphale, Vol. 33, Vol. 78Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 31, No. 7Psychiatric Clinics of North America, Vol. 30, No. 3CNS Spectrums, Vol. 12, No. 1Glutamatergic drugs for schizophrenia19 April 2006 | Cochrane Database of Systematic Reviews, Vol. 11 Suppl 3Neurotoxicity Research, Vol. 10, No. 3-4Cellular and Molecular Neurobiology, Vol. 26, No. 4-6Biological Psychiatry, Vol. 60, No. 6Pharmacology Biochemistry and Behavior, Vol. 84, No. 2Schizophrenia Research, Vol. 88, No. 1-3Clinical Neuropharmacology, Vol. 29, No. 1Current Opinion in Psychiatry, Vol. 19, No. 2Polypharmazie in der Behandlung der SchizophrenieInhibition of System A-mediated glycine transport in cortical synaptosomes by therapeutic concentrations of clozapine: implications for mechanisms of action27 July 2004 | Molecular Psychiatry, Vol. 10, No. 3Psychopharmacology, Vol. 179, No. 1Psychopharmacology, Vol. 179, No. 1Psychiatry Research: Neuroimaging, Vol. 138, No. 1Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs3 August 2004 | Molecular Psychiatry, Vol. 10, No. 1Behavioural Pharmacology, Vol. 16, No. 8Psychiatric Genetics, Vol. 15, No. 3CNS Drugs, Vol. 19, No. 10Glutamate as a therapeutic target in psychiatric disorders27 July 2004 | Molecular Psychiatry, Vol. 9, No. 11Schizophrenia Research, Vol. 66, No. 2-3Biochemical Pharmacology, Vol. 68, No. 8Biological Psychiatry, Vol. 56, No. 5Schizophrenia Research, Vol. 69, No. 2-3Schizophrenia Research, Vol. 71, No. 2-3Sense and non-sense of polypharmacy: increasing efficacy, decreasing compliance?16 April 2020 | European Psychiatry, Vol. 18, No. S2D-Cycloserine facilitates synaptic plasticity but impairs glutamatergic neurotransmission in rat hippocampal slicesBritish Journal of Pharmacology, Vol. 140, No. 6Biological Psychiatry, Vol. 54, No. 11Pharmacology & Therapeutics, Vol. 97, No. 2Identification of a novel variant of the human NR2B gene promoter region and its possible association with schizophrenia12 December 2002 | Molecular Psychiatry, Vol. 7, No. 10Glutamatergic Mechanisms in SchizophreniaAnnual Review of Pharmacology and Toxicology, Vol. 42, No. 1Placebo-Controlled Trial of d-Cycloserine Added to Conventional Neuroleptics, Olanzapine, or Risperidone in SchizophreniaUriel Heresco-Levy, M.D., Marina Ermilov, M.D., Jonathan Shimoni, M.A., Baruch Shapira, M.D., Gail Silipo, M.A., and Daniel C. Javitt, M.D., Ph.D.1 March 2002 | American Journal of Psychiatry, Vol. 159, No. 3Journal of Psychiatric Research, Vol. 36, No. 1Schizophrenia Research, Vol. 56, No. 1-2The Emerging Role of Glutamate in the Pathophysiology and Treatment of SchizophreniaDonald C. Goff, M.D., and Joseph T. Coyle, M.D.1 September 2001 | American Journal of Psychiatry, Vol. 158, No. 9Augmenting antipsychotic treatment with lamotrigine or topiramate in patients with treatment-resistant schizophrenia: a naturalistic caseseries outcome study1 July 2016 | Journal of Psychopharmacology, Vol. 15, No. 4Hippocampus, Vol. 11, No. 5Human Psychopharmacology: Clinical and Experimental, Vol. 16, No. 2Expert Opinion on Therapeutic Targets, Vol. 5, No. 4Differential Efficacy of Olanzapine for Deficit and Nondeficit Negative Symptoms in SchizophreniaAlex Kopelowicz, M.D., Roberto Zarate, Ph.D., Konstantinos Tripodis, M.D., Veronica Gonzalez, B.A., and Jim Mintz, Ph.D.1 June 2000 | American Journal of Psychiatry, Vol. 157, No. 6Intracellular Modulation of NMDA Receptor Function by Antipsychotic Drugs1 June 2000 | The Journal of Neuroscience, Vol. 20, No. 11Placebo-Controlled Trial of Glycine Added to Clozapine in SchizophreniaA. Eden Evins, M.D., Sandra M. Fitzgerald, M.D., Lara Wine, B.S., Roseanne Rosselli, B.A., and Donald C. Goff, M.D.1 May 2000 | American Journal of Psychiatry, Vol. 157, No. 5Behavioral Pharmacology, Vol. 11, No. 7, Vol. 20000744d-Serine Added to Clozapine for the Treatment of SchizophreniaGuochuan E. Tsai, M.D., Ph.D., Pinchen Yang, M.D., Li-Chen Chung, M.S., I-Ching Tsai, B.S., Chung-Wen Tsai, and Joseph T. Coyle, M.D.1 November 1999 | American Journal of Psychiatry, Vol. 156, No. 11Glutamatergic Augmentation Strategies for Cognitive Impairment in SchizophreniaPsychiatric Annals, Vol. 29, No. 11Effect of Clozapine and Adjunctive High-Dose Glycine in Treatment-Resistant SchizophreniaSteven G. Potkin, M.D., Yi Jin, M.D., Blynn G. Bunney, Ph.D., Jerome Costa, M.D., and Bala Gulasekaram, M.D.1 January 1999 | American Journal of Psychiatry, Vol. 156, No. 1Biological Psychiatry, Vol. 45, No. 1Biological Psychiatry, Vol. 45, No. 9Biological Psychiatry, Vol. 45, No. 4Biological Psychiatry, Vol. 46, No. 3Mental Retardation and Developmental Disabilities Research Reviews, Vol. 4, No. 1Biological Psychiatry, Vol. 44, No. 8Biological Psychiatry, Vol. 44, No. 11Journal of Neural Transmission, Vol. 104, No. 6-7Schizophrenia Research, Vol. 27, No. 2-3Schizophrenia Research, Vol. 28, No. 2-3 Volume 153Issue 12 December 1996Pages 1628-1630 Metrics PDF download History Published online 1 April 2006 Published in print 1 December 1996" @default.
• W1845331805 created "2016-06-24" @default.
• W1845331805 creator A5010245045 @default.
• W1845331805 creator A5036342199 @default.
• W1845331805 creator A5056026158 @default.
• W1845331805 creator A5070720166 @default.
• W1845331805 creator A5083540853 @default.
• W1845331805 creator A5086355039 @default.
• W1845331805 date "1996-12-01" @default.
• W1845331805 modified "2023-09-24" @default.
• W1845331805 title "D-cycloserine added to clozapine for patients with schizophrenia" @default.
• W1845331805 cites W1982539986 @default.
• W1845331805 cites W2004534434 @default.
• W1845331805 cites W2011491747 @default.
• W1845331805 cites W2014508839 @default.
• W1845331805 cites W2020740697 @default.
• W1845331805 cites W2052954167 @default.
• W1845331805 cites W2069656785 @default.
• W1845331805 cites W2093248761 @default.
• W1845331805 cites W2165379748 @default.
• W1845331805 cites W2169055778 @default.
• W1845331805 cites W2249014812 @default.
• W1845331805 cites W52175841 @default.
• W1845331805 doi "https://doi.org/10.1176/ajp.153.12.1628" @default.
• W1845331805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8942463" @default.
• W1845331805 hasPublicationYear "1996" @default.
• W1845331805 type Work @default.
• W1845331805 sameAs 1845331805 @default.
• W1845331805 citedByCount "172" @default.
• W1845331805 countsByYear W18453318052012 @default.
• W1845331805 countsByYear W18453318052013 @default.
• W1845331805 countsByYear W18453318052014 @default.
• W1845331805 countsByYear W18453318052015 @default.
• W1845331805 countsByYear W18453318052016 @default.
• W1845331805 countsByYear W18453318052017 @default.
• W1845331805 countsByYear W18453318052018 @default.
• W1845331805 countsByYear W18453318052019 @default.
• W1845331805 countsByYear W18453318052020 @default.
• W1845331805 countsByYear W18453318052021 @default.
• W1845331805 countsByYear W18453318052022 @default.
• W1845331805 countsByYear W18453318052023 @default.
• W1845331805 crossrefType "journal-article" @default.
• W1845331805 hasAuthorship W1845331805A5010245045 @default.
• W1845331805 hasAuthorship W1845331805A5036342199 @default.
• W1845331805 hasAuthorship W1845331805A5056026158 @default.
• W1845331805 hasAuthorship W1845331805A5070720166 @default.
• W1845331805 hasAuthorship W1845331805A5083540853 @default.
• W1845331805 hasAuthorship W1845331805A5086355039 @default.
• W1845331805 hasConcept C118552586 @default.
• W1845331805 hasConcept C142724271 @default.
• W1845331805 hasConcept C15744967 @default.
• W1845331805 hasConcept C2776412080 @default.
• W1845331805 hasConcept C2780864610 @default.
• W1845331805 hasConcept C2781069245 @default.
• W1845331805 hasConcept C2781122200 @default.
• W1845331805 hasConcept C71924100 @default.
• W1845331805 hasConcept C98274493 @default.
• W1845331805 hasConceptScore W1845331805C118552586 @default.
• W1845331805 hasConceptScore W1845331805C142724271 @default.
• W1845331805 hasConceptScore W1845331805C15744967 @default.
• W1845331805 hasConceptScore W1845331805C2776412080 @default.
• W1845331805 hasConceptScore W1845331805C2780864610 @default.
• W1845331805 hasConceptScore W1845331805C2781069245 @default.
• W1845331805 hasConceptScore W1845331805C2781122200 @default.
• W1845331805 hasConceptScore W1845331805C71924100 @default.
• W1845331805 hasConceptScore W1845331805C98274493 @default.
• W1845331805 hasIssue "12" @default.
• W1845331805 hasLocation W18453318051 @default.
• W1845331805 hasLocation W18453318052 @default.
• W1845331805 hasOpenAccess W1845331805 @default.
• W1845331805 hasPrimaryLocation W18453318051 @default.
• W1845331805 hasRelatedWork W1556261663 @default.
• W1845331805 hasRelatedWork W2274792035 @default.
• W1845331805 hasRelatedWork W2370458311 @default.
• W1845331805 hasRelatedWork W2372091399 @default.
• W1845331805 hasRelatedWork W2489248750 @default.
• W1845331805 hasRelatedWork W3033027257 @default.
• W1845331805 hasRelatedWork W4210998453 @default.
• W1845331805 hasRelatedWork W4245148164 @default.
• W1845331805 hasRelatedWork W4293241744 @default.
• W1845331805 hasRelatedWork W4317934569 @default.
• W1845331805 hasVolume "153" @default.
• W1845331805 isParatext "false" @default.
• W1845331805 isRetracted "false" @default.
• W1845331805 magId "1845331805" @default.
• W1845331805 workType "article" @default.